Eris Lifesciences Ltd
NSE:ERIS

Watchlist Manager
Eris Lifesciences Ltd Logo
Eris Lifesciences Ltd
NSE:ERIS
Watchlist
Price: 1 374.2 INR 0.53% Market Closed
Market Cap: 187B INR
Have any thoughts about
Eris Lifesciences Ltd?
Write Note

Eris Lifesciences Ltd
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Eris Lifesciences Ltd
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
Eris Lifesciences Ltd
NSE:ERIS
Note Receivable
â‚ą499.9m
CAGR 3-Years
79%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Note Receivable
â‚ą3.7B
CAGR 3-Years
9%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Note Receivable
â‚ą3.3B
CAGR 3-Years
1 392%
CAGR 5-Years
45%
CAGR 10-Years
0%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Note Receivable
â‚ą10.9B
CAGR 3-Years
-35%
CAGR 5-Years
-18%
CAGR 10-Years
-2%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Note Receivable
â‚ą2.3B
CAGR 3-Years
87%
CAGR 5-Years
18%
CAGR 10-Years
7%
M
Mankind Pharma Ltd
NSE:MANKIND
Note Receivable
â‚ą1.5B
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Eris Lifesciences Ltd
Glance View

Market Cap
186.9B INR
Industry
Pharmaceuticals

Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-06-29. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals and nutrients (VMN). The firm's brands include Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited and Eris Healthcare Private Limited.

ERIS Intrinsic Value
1 082.77 INR
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Eris Lifesciences Ltd's Note Receivable?
Note Receivable
499.9m INR

Based on the financial report for Jun 30, 2024, Eris Lifesciences Ltd's Note Receivable amounts to 499.9m INR.

What is Eris Lifesciences Ltd's Note Receivable growth rate?
Note Receivable CAGR 5Y
45%

Over the last year, the Note Receivable growth was 807%. The average annual Note Receivable growth rates for Eris Lifesciences Ltd have been 79% over the past three years , 45% over the past five years .

Back to Top